

Sarah E Ferguson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3412194/publications.pdf>

Version: 2024-02-01

72
papers

1,872
citations

361413

20
h-index

289244

40
g-index

73
all docs

73
docs citations

73
times ranked

3578
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
2	Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. <i>JAMA Surgery</i> , 2021, 156, 157.	4.3	118
3	Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. <i>Cancer</i> , 2014, 120, 3932-3939.	4.1	114
4	Impact of surgical approach on oncologic outcomes in women undergoing radical hysterectomy for cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 619.e1-619.e24.	1.3	102
5	Laparoscopic and robotic hysterectomy in endometrial cancer patients with obesity: a systematic review and meta-analysis of conversions and complications. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 410-428.e19.	1.3	87
6	Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. <i>Gynecologic Oncology</i> , 2014, 133, 229-233.	1.4	73
7	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. <i>Cancer</i> , 2012, 118, 681-688.	4.1	71
8	The Fallopian Tube as the Origin of High Grade Serous Ovarian Cancer: Review of a Paradigm Shift. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2014, 36, 133-140.	0.7	70
9	A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery. <i>Gynecologic Oncology</i> , 2009, 114, 111-116.	1.4	52
10	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , 2015, 139, 268-274.	1.4	50
11	Prospective cohort study comparing quality of life and sexual health outcomes between women undergoing robotic, laparoscopic and open surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 149, 476-483.	1.4	50
12	Towards the validation of a new, blended theoretical model of fear of cancer recurrence. <i>Psycho-Oncology</i> , 2018, 27, 2594-2601.	2.3	49
13	Protocol of a randomized controlled trial of the fear of recurrence therapy (FORT) intervention for women with breast or gynecological cancer. <i>BMC Cancer</i> , 2016, 16, 291.	2.6	45
14	Preterm premature rupture of membranes Nutritional and socioeconomic factors. <i>Obstetrics and Gynecology</i> , 2002, 100, 1250-1256.	2.4	40
15	Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 367.e1-367.e39.	1.3	39
16	Risk-Reducing Salpingectomy in Canada: A Survey of Obstetrician-Gynaecologists. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 627-634.	0.7	34
17	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016, 141, 148-154.	1.4	34
18	External Validation of O-RADS US Risk Stratification and Management System. <i>Radiology</i> , 2022, 304, 114-120.	7.3	28

#	ARTICLE	IF	CITATIONS
19	Heparin for pregnant women with acquired or inherited thrombophilias. The Cochrane Library, 2003, , CD003580.	2.8	26
20	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. Gynecologic Oncology, 2016, 141, 559-563.	1.4	25
21	Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective. Obstetrics and Gynecology International, 2018, 2018, 1-10.	1.3	23
22	Association of bilateral salpingo-oophorectomy with all cause and cause specific mortality: population based cohort study. BMJ, The, 2021, 375, e067528.	6.0	22
23	Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas. American Journal of Surgical Pathology, 2019, 43, 591-600.	3.7	21
24	The prognostic value of perioperative, pre-systemic therapy CA-125 levels in patients with high-grade serous ovarian cancer. International Journal of Gynecology and Obstetrics, 2018, 140, 247-252.	2.3	18
25	A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer. Gynecologic Oncology, 2016, 140, 36-41.	1.4	17
26	Barriers to care for women with low-grade endometrial cancer and morbid obesity: a qualitative study. BMJ Open, 2019, 9, e026872.	1.9	16
27	Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer. Journal of Oncology Practice, 2019, 15, e1066-e1075.	2.5	16
28	The optimal time for surgery in women with serous ovarian cancer. Canadian Journal of Surgery, 2016, 59, 223-232.	1.2	16
29	Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. Cancer, 2020, 126, 4886-4894.	4.1	15
30	Confirmatory factor analysis of the Sexual Adjustment and Body Image Scale in women with gynecologic cancer. Cancer, 2012, 118, 3095-3104.	4.1	13
31	Comparison of three surgical approaches for staging lymphadenectomy in high-risk endometrial cancer. International Journal of Gynecology and Obstetrics, 2017, 136, 315-319.	2.3	13
32	Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?. Gynecologic Oncology, 2017, 147, 54-60.	1.4	12
33	Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system. Gynecologic Oncology, 2020, 158, 747-753.	1.4	12
34	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
35	Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis. Gynecologic Oncology, 2020, 158, 218-228.	1.4	12
36	An Integrative DNA Sequencing and Methylation Panel to Assess Mismatch Repair Deficiency. Journal of Molecular Diagnostics, 2021, 23, 242-252.	2.8	12

#	ARTICLE	IF	CITATIONS
37	The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	11
38	Implementing a Cervical Sentinel Lymph Node Biopsy Program: Quality Improvement in Gynaecologic Oncology. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 659-667.	0.7	10
39	The use of indocyanine green fluorescence angiography to assess anastomotic perfusion following bowel resection in surgery for gynecologic malignancies - A report of 100 consecutive anastomoses. <i>Gynecologic Oncology</i> , 2020, 158, 402-406.	1.4	10
40	Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 136, 311-316.	1.4	9
41	Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study. <i>Gynecologic Oncology</i> , 2020, 157, 745-753.	1.4	9
42	Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. <i>Gynecologic Oncology</i> , 2021, 161, 221-227.	1.4	9
43	Practice variation in bilateral salpingo-oophorectomy at benign abdominal hysterectomy: a population-based study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 585.e1-585.e30.	1.3	9
44	Endometrial cancer. <i>Cmaj</i> , 2021, 193, E1423-E1423.	2.0	9
45	Empowering patients and caregivers with knowledge: The development of a nurse-led gynecologic oncology chemotherapy education class. <i>Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique</i> , 2018, 28, 4-7.	0.5	9
46	Ovarian cancer incidence and death in average-risk women undergoing bilateral salpingo-oophorectomy at benign hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 220.e1-220.e26.	1.3	8
47	Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. <i>Gynecologic Oncology</i> , 2021, 162, 12-17.	1.4	7
48	Management of gynecologic cancer: Choosing radiotherapy wisely by 3 Southern Ontario academic centers during the COVID-19 pandemic. <i>Radiotherapy and Oncology</i> , 2020, 151, 15-16.	0.6	6
49	Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. <i>Cancer</i> , 2021, 127, 3082-3091.	4.1	6
50	Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer. <i>Current Oncology</i> , 2022, 29, 1123-1135.	2.2	6
51	An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. <i>Current Oncology</i> , 2021, 28, 1114-1124.	2.2	4
52	Brachy-ing Unresectable Endometrial Cancers with Magnetic Resonance Guidance. <i>Cureus</i> , 2018, 10, e2274.	0.5	4
53	Pre-operative wait times in high-grade non-endometrioid endometrial cancer: Do surgical delays impact patient survival?. <i>Gynecologic Oncology</i> , 2022, 164, 333-340.	1.4	4
54	Class III Obesity and Other Factors Associated with Longer Wait Times for Endometrial Cancer Surgery: A Population-Based Study. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2020, 42, 1093-1102.e3.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103336.	4.4	3
56	The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches. <i>Gynecologic Oncology</i> , 2021, 162, 97-106.	1.4	3
57	Efficacy and toxicity of intraperitoneal chemotherapy as compared to intravenous chemotherapy in the treatment of patients with advanced ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2021, , .	2.3	3
58	Treatment outcomes and predictive factors in patients ≥70 years old with advanced ovarian cancer. <i>Journal of Surgical Oncology</i> , 2021, , .	1.7	3
59	Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study. <i>Gynecologic Oncology</i> , 2022, 164, 522-528.	1.4	3
60	A prospective comparison of costs between robotics, laparoscopy, and laparotomy in endometrial cancer among women with Class III obesity or higher. <i>Journal of Surgical Oncology</i> , 2022, 125, 747-753.	1.7	3
61	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 96-97.	1.3	2
62	Evaluating the effect of a group pre-treatment chemotherapy psycho-education session for chemotherapy-naïve gynecologic cancer patients and their caregivers. <i>Gynecologic Oncology</i> , 2021, 160, 234-243.	1.4	2
63	An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16586-e16586.	1.6	1
64	Long-term survival outcomes of intravenous versus intraperitoneal chemotherapy in the treatment of advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6046-6046.	1.6	1
65	Risk stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with gynecological cancers: Preliminary results from a prospective single-center study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6062-6062.	1.6	1
66	Implementation of a standardized voiding protocol after minimally invasive surgery: A quality improvement initiative. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 159, 696-701.	2.3	1
67	Performance characteristics of brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed ovarian cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, e22525-e22525.	1.6	0
68	Sentinel Lymph Node Concept in High-Risk Profile Endometrial Cancer”Reply. <i>JAMA Surgery</i> , 2021, 156, 799-800.	4.3	0
69	Screening for Lynch syndrome in unselected women with endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5508-5508.	1.6	0
70	Ovarian cancer pathway map development as an approach to identifying priority areas for quality improvement in Ontario.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18190-e18190.	1.6	0
71	Accessing care: Experiences and perceptions of morbidly obese women diagnosed with low-grade endometrial cancer”A qualitative study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18658-e18658.	1.6	0
72	Sentinel lymph node biopsy in high-grade endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, , .	1.3	0